You are here

FDA, Bayer Withdraw Sargramostim After Increased Reports of Adverse Events

January 22, 2008 -- Bayer and FDA informed healthcare professionals of the market withdrawal of the current liquid formulation of Leukine, a growth factor that helps fight infection and disease in appropriate patients by enhancing immune cell function.

The product was withdrawn because of an upward trend in spontaneous reports of adverse reactions, including syncope (fainting), which are temporally correlated with a change in the formulation of liquid Leukine to include edetate disodium (EDTA). The upward trend in adverse reaction reporting rates has not been observed with the use of lyophilized Leukine. Healthcare professionals should immediately stop using liquid Leukine and return unused vials to the manufacturer.

View the 'Dear Healthcare Professional' letter: Click here.

Source: Food and Drug Administration

Recent Headlines

Rationing, canceled treatments, and fearful patients
Your heart will thank you
Seems like the 2013 Guidelines are having an impact
Biomarker blood tests pick up subtle clues
Meeting 'zombie cells' along the way
A new 'road map' might make it easier
New drug addresses bacterial resistance to standard therapy
Hovering flights lower packages by cable and winch